
    
      The primary objective of this phase 1 study is to determine the RP2D of HQP1351 in patients
      with GIST or other solid tumors. The secondary objective is to assess the safety,
      tolerability, PK and preliminary anti-tumor activities of HQP1351 in Patients With GIST or
      Other Solid Tumors.
    
  